サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1459621

標的治療薬の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2024年から2032年までの予測

Global Targeted Therapeutics Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032
出版日: | 発行: Value Market Research | ページ情報: 英文 226 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.90円
標的治療薬の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2024年から2032年までの予測
出版日: 2024年03月01日
発行: Value Market Research
ページ情報: 英文 226 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

標的治療薬市場の世界需要は、2023年の705億8,000万米ドルから2032年には約1,343億米ドルの市場規模に達すると推定され、調査期間2024～2032年のCAGRは7.41%です。

標的治療薬は、疾患プロセスに関与する特定の分子や経路を選択的に標的とする治療薬法の一種です。従来の広範囲な治療薬とは異なり、標的治療薬は、健康な組織への悪影響を最小限に抑えながら、正確で効果的な治療薬を提供することを目的としています。このような治療薬法ではしばしば、モノクローナル抗体、低分子阻害剤、遺伝子治療薬、免疫療法などが利用され、がん細胞の増殖を阻害したり、異常なシグナル伝達経路を阻害したり、免疫系の反応を調節したりします。

市場力学

分子生物学とゲノミクスの進歩により、分子レベルでの疾病メカニズムがより深く理解されるようになり、疾病の原因分子を正確に標的とし、副作用を最小限に抑え、有効性を向上させる標的療法を開発する道が開かれました。さらに、がん、自己免疫疾患、心血管疾患などの慢性疾患の罹患率の増加は、より効果的で個別化された治療薬オプションに対する需要を高め、標的治療薬市場をさらに牽引しています。さらに、標的治療薬の承認プロセスの迅速化を目指した規制当局の取り組みや、製薬企業による研究開発への投資の増加が、市場の成長に寄与しています。さらに、標的治療薬から利益を得る可能性が最も高い個人を特定するためのコンパニオン診断の採用が増加していることも、市場浸透を高めています。最後に、次世代シーケンシングや遺伝子編集技術などの技術進歩は、新規標的治療薬開発の新たな道を開き、技術革新を促進して市場拡大を促進しています。しかし、医薬品開発における規制上の課題、研究開発コストの高さ、確立された治療薬法との競合は、標的治療薬市場を制限する可能性があります。

調査レポートは、ポーターのファイブフォースモデル、市場魅力度分析、バリューチェーン分析をカバーしています。これらのツールは、業界構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールは、標的治療薬の世界市場における各セグメントを包括的に評価することもできます。標的治療薬業界の成長と動向は、この調査に全体的なアプローチを記載しています。

市場セグメンテーション

標的治療薬市場レポートのこのセクションは、国と地域レベルのセグメントに関する詳細なデータを提供し、それによって戦略家が今後の機会とともに、それぞれの製品やサービスの対象層を特定するのに役立ちます。

タイプ別

  • モノクローナル抗体（血管新生阻害剤、Her-2標的薬、抗Cd20モノクローナル抗体）
  • 低分子（チロシンキナーゼ阻害剤）

用途別

  • 乳がん
  • 大腸がん
  • 白血病
  • 肺がん
  • リンパ腫
  • 多発性硬化症
  • 腎臓がん
  • 湿性加齢黄斑変性症
  • その他（卵巣がん、卵管がん、前立腺がん、膵臓がん）

流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

地域別分析

このセクションでは、北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカにおける標的治療薬市場の現在と将来の需要を強調する地域展望をカバーします。さらに、著名な全地域における個々の用途セグメントの需要・推定・予測にも焦点を当てています。

カスタム要件がある場合は、お問い合わせください。当社の調査チームは、お客様のニーズに応じてカスタマイズしたレポートを提供することができます。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 標的治療薬-産業分析

  • イントロダクション：市場力学
  • 市場促進要因
  • 市場抑制要因
  • 機会
  • 業界動向
  • ポーターのファイブフォース分析
  • 市場魅力度分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
    • 原材料リスト
    • 原材料メーカー一覧
    • 主要原材料の価格動向
  • 潜在的バイヤー一覧
  • マーケティングチャネル
    • 直接マーケティング
    • 間接マーケティング
    • マーケティングチャネル発展動向

第5章 標的治療薬の世界市場分析：タイプ別

  • タイプ別概要
  • 実績データと予測データ
  • タイプ別分析
  • モノクローナル抗体（血管新生阻害薬、HER-2標的薬、抗CD20モノクローナル抗体）
  • 低分子（チロシンキナーゼ阻害剤）

第6章 標的治療薬の世界市場分析：用途別

  • 用途別概要
  • 実績データと予測データ
  • 用途別分析
  • 乳がん
  • 大腸がん
  • 白血病
  • 肺がん
  • リンパ腫
  • 多発性硬化症
  • 腎臓がん
  • 湿性加齢黄斑変性
  • その他（卵巣がん、卵管がん、前立腺がん、膵臓がん）

第7章 標的治療薬の世界市場分析：流通チャネル別

  • 流通チャネル別概要
  • 実績データと予測データ
  • 流通チャネル別分析
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第8章 標的治療薬の世界市場分析：地域別

  • 地域別展望
  • イントロダクション
  • 北米売上分析
    • 概要、実績と予測
    • 北米：セグメント別
    • 北米：国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州売上分析
    • 概要、実績と予測
    • 欧州：セグメント別
    • 欧州：国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他の欧州
  • アジア太平洋売上分析
    • 概要、実績と予測
    • アジア太平洋：セグメント別
    • アジア太平洋：国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • 東南アジア
    • その他のアジア太平洋
  • ラテンアメリカ売上分析
    • 概要、実績と予測
    • ラテンアメリカ：セグメント別
    • ラテンアメリカ：国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他のラテンアメリカ
  • 中東・アフリカ売上分析
    • 概要、実績と予測
    • 中東・アフリカ：セグメント別
    • 中東・アフリカ：国別
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他の中東・アフリカ

第9章 標的治療薬企業の競合情勢

  • 標的治療薬市場の競合
  • 提携・協力・契約
  • 合併・買収
  • 新製品の上市
  • その他の開発

第10章 企業プロファイル

  • 企業シェア分析
  • 市場集中度
  • Sanofi
  • GlaxoSmithKline plc.
  • Takeda Pharmaceutical Company Ltd.
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd.
  • AstraZeneca
  • Seagen Inc.
  • Bayer AG
  • Amgen Inc.
  • Bristol-Myers Squibb Company
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers : Impact Analysis
  • Restraints : Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • List of Potential Buyers
  • Analysis by Type (USD MN)
  • Monoclonal Antibodies (Angiogenesis Inhibitors, HER-2 Targeted Agents, and Anti-CD20 Monoclonal Antibodies) Market Sales by Geography (USD MN)
  • Small Molecule (Tyrosine Kinase Inhibitors) Market Sales by Geography (USD MN)
  • Analysis Market by Application (USD MN)
  • Breast Cancer Market Sales by Geography (USD MN)
  • Colorectal Cancer Market Sales by Geography (USD MN)
  • Leukemia Market Sales by Geography (USD MN)
  • Lung Cancer Market Sales by Geography (USD MN)
  • Lymphoma Market Sales by Geography (USD MN)
  • Multiple Sclerosis Market Sales by Geography (USD MN)
  • Renal Cancer Market Sales by Geography (USD MN)
  • Wet Age-related Macular Degeneration Market Sales by Geography (USD MN)
  • Others (Ovarian Cancer, Fallopian Tube Cancer, Prostate Cancer, and Pancreatic Cancer) Market Sales by Geography (USD MN)
  • Analysis by Distribution Channel (USD MN)
  • Hospital Pharmacies Market Sales by Geography (USD MN)
  • Retail Pharmacies Market Sales by Geography (USD MN)
  • Online Pharmacies Market Sales by Geography (USD MN)
  • Global Targeted Therapeutics Market Sales by Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United State Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate by Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Targeted Therapeutics Report
  • Market Research Process
  • Market Research Methodology
  • Global Targeted Therapeutics Market Size, by Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis by Type
  • Market Attractiveness Analysis by Application
  • Market Attractiveness Analysis by Distribution Channel
  • Market Attractiveness Analysis by Region
  • Value Chain Analysis
  • Global Market Analysis by Type (USD MN)
  • Monoclonal Antibodies (Angiogenesis Inhibitors, HER-2 Targeted Agents, and Anti-CD20 Monoclonal Antibodies) Market Sales by Geography (USD MN)
  • Small Molecule (Tyrosine Kinase Inhibitors) Market Sales by Geography (USD MN)
  • Global Market Analysis by Application (USD MN)
  • Breast Cancer Market Sales by Geography (USD MN)
  • Colorectal Cancer Market Sales by Geography (USD MN)
  • Leukemia Market Sales by Geography (USD MN)
  • Lung Cancer Market Sales by Geography (USD MN)
  • Lymphoma Market Sales by Geography (USD MN)
  • Multiple Sclerosis Market Sales by Geography (USD MN)
  • Renal Cancer Market Sales by Geography (USD MN)
  • Wet Age-related Macular Degeneration Market Sales by Geography (USD MN)
  • Others (Ovarian Cancer, Fallopian Tube Cancer, Prostate Cancer, and Pancreatic Cancer) Market Sales by Geography (USD MN)
  • Global Market Analysis by Distribution Channel (USD MN)
  • Hospital Pharmacies Market Sales by Geography (USD MN)
  • Retail Pharmacies Market Sales by Geography (USD MN)
  • Online Pharmacies Market Sales by Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

目次
Product Code: VMR112114054

The global demand for Targeted Therapeutics Market is presumed to reach the market size of nearly USD 134.3 Billion by 2032 from USD 70.58 Billion in 2023 with a CAGR of 7.41% under the study period 2024 - 2032.

Targeted therapeutics is a class of medical treatments that selectively target specific molecules or pathways involved in disease processes. Unlike traditional broad-spectrum therapies, targeted therapeutics aim to deliver precise and effective treatment while minimizing adverse effects on healthy tissues. These therapies often utilize monoclonal antibodies, small molecule inhibitors, gene therapies, or immunotherapies to interfere with cancer cell growth, inhibit abnormal signaling pathways, or modulate the immune system's response.

MARKET DYNAMICS

Progress in molecular biology & genomics has allowed for a more profound comprehension of disease mechanisms at the molecular level, paving the way for developing targeted therapies that can precisely target disease-causing molecules, minimizing side effects and improving efficacy. Additionally, the increasing incidence of chronic diseases such as cancer, autoimmune disorders, and cardiovascular diseases has increased the demand for more effective and personalized treatment options, further driving the market for targeted therapeutics. Moreover, regulatory initiatives aimed at expediting the approval process for targeted drugs and increasing investments in research and development by pharmaceutical companies are contributing to the market growth. Furthermore, the rising adoption of companion diagnostics to pinpoint individuals most likely to gain from targeted therapies is enhancing market penetration. Lastly, technological advancements such as next-generation sequencing and gene editing technologies open new avenues for developing novel targeted therapeutics, fostering innovation and driving market expansion. However, regulatory challenges in drug development, high research & development costs, and competition from established treatment modalities may restrict the targeted therapeutics Market.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of targeted therapeutics. The growth and trends of targeted therapeutics industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the targeted therapeutics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

  • Monoclonal Antibodies (Angiogenesis Inhibitors, Her-2 Targeted Agents, And Anti-Cd20 Monoclonal Antibodies)
  • Small Molecule (Tyrosine Kinase Inhibitors)

By Application

  • Breast Cancer
  • Colorectal Cancer
  • Leukemia
  • Lung Cancer
  • Lymphoma
  • Multiple Sclerosis
  • Renal Cancer
  • Wet Age-Related Macular Degeneration
  • Others (Ovarian Cancer, Fallopian Tube Cancer, Prostate Cancer, And Pancreatic Cancer)

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Targeted Therapeutics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Targeted Therapeutics market include Sanofi, GlaxoSmithKline plc., Takeda Pharmaceutical Company Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca, Seagen, Inc., Bayer AG, Amgen, Inc., Bristol-Myers Squibb Company. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . TARGETED THERAPEUTICS - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Type
    • 3.7.2 Market Attractiveness Analysis By Application
    • 3.7.3 Market Attractiveness Analysis By Distribution Channel
    • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL TARGETED THERAPEUTICS MARKET ANALYSIS BY TYPE

  • 5.1 Overview by Type
  • 5.2 Historical and Forecast Data
  • 5.3 Analysis by Type
  • 5.4 Monoclonal Antibodies (Angiogenesis Inhibitors, HER-2 Targeted Agents, and Anti-CD20 Monoclonal Antibodies) Historic and Forecast Sales by Regions
  • 5.5 Small Molecule (Tyrosine Kinase Inhibitors) Historic and Forecast Sales by Regions

6 . GLOBAL TARGETED THERAPEUTICS MARKET ANALYSIS BY APPLICATION

  • 6.1 Overview by Application
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Application
  • 6.4 Breast Cancer Historic and Forecast Sales by Regions
  • 6.5 Colorectal Cancer Historic and Forecast Sales by Regions
  • 6.6 Leukemia Historic and Forecast Sales by Regions
  • 6.7 Lung Cancer Historic and Forecast Sales by Regions
  • 6.8 Lymphoma Historic and Forecast Sales by Regions
  • 6.9 Multiple Sclerosis Historic and Forecast Sales by Regions
  • 6.10. Renal Cancer Historic and Forecast Sales by Regions
  • 6.11 Wet Age-related Macular Degeneration Historic and Forecast Sales by Regions
  • 6.12 Others (Ovarian Cancer, Fallopian Tube Cancer, Prostate Cancer, and Pancreatic Cancer) Historic and Forecast Sales by Regions

7 . GLOBAL TARGETED THERAPEUTICS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

  • 7.1 Overview by Distribution Channel
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by Distribution Channel
  • 7.4 Hospital Pharmacies Historic and Forecast Sales by Regions
  • 7.5 Retail Pharmacies Historic and Forecast Sales by Regions
  • 7.6 Online Pharmacies Historic and Forecast Sales by Regions

8 . GLOBAL TARGETED THERAPEUTICS MARKET ANALYSIS BY GEOGRAPHY

  • 8.1. Regional Outlook
  • 8.2. Introduction
  • 8.3. North America Sales Analysis
    • 8.3.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.3.2. North America By Segment Sales Analysis
    • 8.3.3. North America By Country Sales Analysis
    • 8.3.4. United State Sales Analysis
    • 8.3.5. Canada Sales Analysis
    • 8.3.6. Mexico Sales Analysis
  • 8.4. Europe Sales Analysis
    • 8.4.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.4.2. Europe by Segment Sales Analysis
    • 8.4.3. Europe by Country Sales Analysis
    • 8.4.4. United Kingdom Sales Analysis
    • 8.4.5. France Sales Analysis
    • 8.4.6. Germany Sales Analysis
    • 8.4.7. Italy Sales Analysis
    • 8.4.8. Russia Sales Analysis
    • 8.4.9. Rest Of Europe Sales Analysis
  • 8.5. Asia Pacific Sales Analysis
    • 8.5.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.5.2. Asia Pacific by Segment Sales Analysis
    • 8.5.3. Asia Pacific by Country Sales Analysis
    • 8.5.4. China Sales Analysis
    • 8.5.5. India Sales Analysis
    • 8.5.6. Japan Sales Analysis
    • 8.5.7. South Korea Sales Analysis
    • 8.5.8. Australia Sales Analysis
    • 8.5.9. South East Asia Sales Analysis
    • 8.5.10. Rest Of Asia Pacific Sales Analysis
  • 8.6. Latin America Sales Analysis
    • 8.6.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.6.2. Latin America by Segment Sales Analysis
    • 8.6.3. Latin America by Country Sales Analysis
    • 8.6.4. Brazil Sales Analysis
    • 8.6.5. Argentina Sales Analysis
    • 8.6.6. Peru Sales Analysis
    • 8.6.7. Chile Sales Analysis
    • 8.6.8. Rest of Latin America Sales Analysis
  • 8.7. Middle East & Africa Sales Analysis
    • 8.7.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.7.2. Middle East & Africa by Segment Sales Analysis
    • 8.7.3. Middle East & Africa by Country Sales Analysis
    • 8.7.4. Saudi Arabia Sales Analysis
    • 8.7.5. UAE Sales Analysis
    • 8.7.6. Israel Sales Analysis
    • 8.7.7. South Africa Sales Analysis
    • 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE TARGETED THERAPEUTICS COMPANIES

  • 9.1. Targeted Therapeutics Market Competition
  • 9.2. Partnership/Collaboration/Agreement
  • 9.3. Merger And Acquisitions
  • 9.4. New Product Launch
  • 9.5. Other Developments

10 . COMPANY PROFILES OF TARGETED THERAPEUTICS INDUSTRY

  • 10.1. Company Share Analysis
  • 10.2. Market Concentration Rate
  • 10.3. Sanofi
    • 10.3.1. Company Overview
    • 10.3.2. Company Revenue
    • 10.3.3. Products
    • 10.3.4. Recent Developments
  • 10.4. GlaxoSmithKline plc.
    • 10.4.1. Company Overview
    • 10.4.2. Company Revenue
    • 10.4.3. Products
    • 10.4.4. Recent Developments
  • 10.5. Takeda Pharmaceutical Company Ltd.
    • 10.5.1. Company Overview
    • 10.5.2. Company Revenue
    • 10.5.3. Products
    • 10.5.4. Recent Developments
  • 10.6. Merck & Co. Inc.
    • 10.6.1. Company Overview
    • 10.6.2. Company Revenue
    • 10.6.3. Products
    • 10.6.4. Recent Developments
  • 10.7. Novartis AG
    • 10.7.1. Company Overview
    • 10.7.2. Company Revenue
    • 10.7.3. Products
    • 10.7.4. Recent Developments
  • 10.8. Pfizer Inc.
    • 10.8.1. Company Overview
    • 10.8.2. Company Revenue
    • 10.8.3. Products
    • 10.8.4. Recent Developments
  • 10.9. F. Hoffmann-La Roche Ltd.
    • 10.9.1. Company Overview
    • 10.9.2. Company Revenue
    • 10.9.3. Products
    • 10.9.4. Recent Developments
  • 10.10. AstraZeneca
    • 10.10.1. Company Overview
    • 10.10.2. Company Revenue
    • 10.10.3. Products
    • 10.10.4. Recent Developments
  • 10.11. Seagen Inc.
    • 10.11.1. Company Overview
    • 10.11.2. Company Revenue
    • 10.11.3. Products
    • 10.11.4. Recent Developments
  • 10.12. Bayer AG
    • 10.12.1. Company Overview
    • 10.12.2. Company Revenue
    • 10.12.3. Products
    • 10.12.4. Recent Developments
  • 10.13. Amgen Inc.
    • 10.13.1. Company Overview
    • 10.13.2. Company Revenue
    • 10.13.3. Products
    • 10.13.4. Recent Developments
  • 10.14. Bristol-Myers Squibb Company
    • 10.14.1. Company Overview
    • 10.14.2. Company Revenue
    • 10.14.3. Products
    • 10.14.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies